Brand VerifiedUnited States

Zoetis Inc.

Zoetis

Zoetis Inc. is the world's leading pure-play animal health company, dominating the global veterinary pharmaceuticals and pet healthcare sector. Founded in 1952 as Pfizer's animal health division before its landmark IPO in 2013, Zoetis is headquartered in Parsippany, New Jersey, USA. With annual revenue of USD 9.467 billion (2025), the company operates 23 manufacturing sites across 11 countries, employing 14,000 employees worldwide. Zoetis commands an unparalleled 69% revenue concentration in companion animal products, powered by blockbuster franchises Simparica Trio and monoclonal antibody pain therapies Librela/Solensia.

Strengths:
• Absolute Market Dominance: Reigning global #1 with USD 95B revenue, unmatched scale across 120+ countries with 42.2B US companion animal revenue alone
• Biologics Manufacturing Supremacy: 23 fully owned manufacturing sites with $590M invested in a new Georgia mAb/vaccine facility and quadrupled capacity at Tullamore, Ireland
• Innovation Pipeline Leadership: Simparica Trio surpassed $10B in single-market US sales; Librela and Solensia remain the only approved NGF-targeting monoclonal antibodies for canine/feline OA pain
• Vertical Integration: Seamless R&D-to-commercial-production closed loop, with Kalamazoo serving as both global R&D HQ and largest manufacturing hub
• Regulatory & Scientific Authority: Over 70 country-level direct operations with deep relationships across FDA, EMA, and global veterinary regulatory bodies
Weaknesses:
• Single-Asset Manufacturing Risk: Complex biologics (mAbs) are produced at single dedicated facilities; any contamination or equipment failure risks localized supply disruptions
• Macroeconomic Sensitivity: Q1 2025 saw US companion animal demand softening due to reduced veterinary clinic visits amid consumer spending pressure
• Premium Pricing Vulnerability: Generic and biosimilar competition from emerging Asian manufacturers threatens long-term pricing power in price-sensitive markets

Business Nature

Zoetis operates as a fully vertically integrated animal health company with extensive in-house R&D and manufacturing capabilities. The company maintains 23 state-of-the-art manufacturing facilities across 11 countries including the US Kalamazoo, Lincoln, Durham, Europe, and Asia-Pacific.

While Zoetis utilizes over 110 third-party CMOs for non-core edge processes, all mission-critical products—particularly complex biologics, monoclonal antibodies, and innovative vaccine platforms—are produced entirely within its proprietary, highly secured facilities. The Kalamazoo, Michigan site serves as both global R&D headquarters and largest manufacturing hub, enabling a seamless research-pilot-scale-commercial production closed loop.

In 2025, Zoetis invested $590 million in a new monoclonal antibody and vaccine manufacturing facility in Douglasville, Georgia, and completed a quadrupling of capacity at its Tullamore, Ireland plant.

Core Business Areas

Companion Animal Pharmaceuticals — Core Business
• Parasiticides: Simparica Trio / Revolution Plus
• Dermatology: Apoquel / Cytopoint
• Pain Management: Librela / Solensia monoclonal antibodies
• Vaccines: Vanguard / Fel-O-Vax
• Anti-infectives and companion animal diagnostics

Industry Rankings

1Top 10 Veterinary Pharmaceuticals & Pet Healthcare Companies

Brand

1Top 10 Veterinary Pharmaceuticals & Pet Healthcare Manufacturers & Suppliers

Mfr

Corporate Report

Zoetis Inc. is a United States-based pure-play animal health company headquartered in Parsippany, New Jersey. Originally founded in 1952 as Pfizer's animal health division and spun off as an independent public company in 2013. With 2025 global revenue of USD 9.467 billion, employing 14,000 people across 23 manufacturing sites in 11 countries, and products sold in over 120 countries.

Core Business

Zoetis is the undisputed global leader in animal health, with companion animal products generating 69% of total revenue. The company's portfolio spans parasiticides (Simparica Trio — the first animal health product to surpass $10B in single-market US sales), dermatology (Apoquel, Cytopoint), and innovative pain management through monoclonal antibody therapies (Librela for canine OA, Solensia for feline OA). Its livestock portfolio covers vaccines, anti-infectives, and medicated feed additives.

Global Presence

Zoetis operates across more than 120 countries with direct operations in over 45 nations. Its 23 manufacturing sites are strategically distributed across the US (Kalamazoo, Lincoln, Durham, Buellton, Union City), Europe, and Asia-Pacific. The Kalamazoo, Michigan facility serves as the company's global R&D headquarters and largest production hub. In 2025, the company expanded further by acquiring a 21-acre manufacturing facility in Melbourne, Australia—its third in the Asia-Pacific region—and invested $590M in a new Georgia biologics facility.

Key Strengths

• Dominant #1 market position with 69% companion animal revenue concentration
• Unmatched biologics manufacturing scale with 23 owned sites and $590M+ in ongoing capacity expansions
• Only company with approved NGF monoclonal antibody therapies for both canine and feline osteoarthritis
• Simparica Trio franchise achieving historic $10B+ single-market revenue milestone
• Deep vertical integration from R&D through commercial production with >70 country-level direct operations

VerityRank Score

VerityRank Score of 89/100

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Parsippany, New Jersey, USA

Founded

1952

Employees

14,000

Factories

23 manufacturing sites across 11 countries

Listing

NYSE: ZTS

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NYSE: ZTS , Zoetis Official Website
SEC EDGAR — Zoetis Filings
Wikipedia — Zoetis

Back to Rankings